CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 1 enrolled
Drug / intervention
Berzosertibdrug
Likely dose
Berzosertib 126 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03309150
NCT03309150Phase 1Completed
CompareCT.gov

A Rollover Study to Provide Continued Treatment With M6620

Merck KGaA, Darmstadt, Germany·interventional·Posted Oct 13, 2017·Updated Nov 29, 2024

In Brief

A Phase 1 clinical trial evaluating Berzosertib for Advanced Stage Solid Tumors. Completed, enrolled 1 participant across 1 site.

Detailed Summary

The main purpose of the study was to monitor the safety of participant receiving long-term treatment of Berzosertib as monotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Stage Solid Tumors
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 13, 2017
Enrollment StartJan 10, 2018
Primary CompletionJan 26, 2024
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 8.7 years ago

Interventions

Berzosertibdrug

Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred.